Bendamustine plus mitoxantrone - A new effective treatment for advanced chronic lymphocytic leukaemia: Results of a phase I/II study

Leukemia and Lymphoma

Volumn 45, Issue 5, 2004, Pages 911-913

  Köppler, Hubert ^a   Heymanns, Jochen ^a   Pandorf, Annette ^a   Weide, Rudolf ^a  

^a Haematology/Oncology Group Practice   (Germany)

Author keywords

B CLL; Bendamustine; Haematotoxicity; Mitoxantrone

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; MITOXANTRONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; INFECTIOUS COMPLICATION; LYMPHADENITIS; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; MITOXANTRONE; NITROGEN MUSTARD COMPOUNDS; OPPORTUNISTIC INFECTIONS; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 11144357625     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000123546     Document Type: Article

References (10)

1. Hallek, M., Schmitt, B., Wilhelm, M., et al. (2001) "FLudarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): Results of a phase II study of the German CLL Study Group", Br. J. Haematol. 114(2), 342-348.
2. O'Brien, S.M., Kantarjian, H.M., Cortes, J., et al. (2001) "REsults of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukaemia", J. Clin. Oncol. 19(5), 1414-1420.
3. Rummel, M.J., Kafer, G., Pfreundschuh, M., et al. (1999) "FLudarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: A German multicenter phase II study", Ann. Oncol. 10(2), 183-188.
4. Seymour, J.F., Grigg, A.P., Szer, J. and Fox, R.M. (2001) "FLudarabine and mitoxEntrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders", Ann. Oncol. 12(10), 1455-1460.
5. Bosch, F., Ferrer, A., Lopez-Guillermo, A., et al. (2002) "FLudarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia", Br. J. Haematol. 119(4), 976-984.
6. Ozegowski, W. and Krebs, D. (1971) "IMET 3393, gamma-(1-Methyl-5-bis-(β-chloräthyl)-amino-benzimidazolyl(2))- butter-säure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste", Zbl. Pharm. 110, 1013-1019.
7. Kath, R., Blumenstengel, K., Fricke, H.J. and Hoffken, K. (2001) "BEndamustine monotherapy in advanced and refractory chronic lymphocytic leukaemia", J. Cancer Res. Clin. Oncol. 127(1), 48-54.
8. Bremer, K. (2002) "HIgh rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas", J. Cancer Res. Clin. Oncol. 128(11), 603-609.
9. Weide, R., Heymanns, J., Gores, A. and Köppler, H. (2002) "BEndamustine/Mitoxantrone/RituximaA (BMR): a new effective regimen for refractory or relapsed indolent lymphomas", Leak Lymphoma 42(2), 327-331.
10. Rai, R.K., Peterson, B.L., Appelbaum, F.R., et al. (2000) "FLudarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia", N. Engl. J. Med. 343(24), 1750-1757.